RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+1.97%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$327M
AUM Growth
+$327M
(-3.1%)
Cap. Flow
-$19.4M
Cap. Flow
% of AUM
-5.94%
Top 10 Holdings %
Top 10 Hldgs %
25.93%
Holding
105
New
8
Increased
44
Reduced
37
Closed
6
Top Buys
| 1 |
Universal Health Services
UHS
|
$7.18M |
| 2 |
Medtronic
MDT
|
$6.87M |
| 3 |
AbbVie
ABBV
|
$6.41M |
| 4 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$4.4M |
| 5 |
Alkermes
ALKS
|
$4.2M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$11.5M |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
$8.22M |
| 3 |
CELG
Celgene Corp
CELG
|
$7.28M |
| 4 |
Biogen
BIIB
|
$6.95M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$6.58M |
Sector Composition
| 1 | Healthcare | 82.32% |
| 2 | Financials | 1.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Alkermes
ALKS
$4.78B
| $11.4M | 3.34% | 266,000 +98,000 | +58% | +$4.2M |
|
|
2
Universal Health Services
UHS
$11.6B
| $10.3M | 3.02% | 98,700 +68,700 | +229% | +$7.18M |
|
|
ALXN
3
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $9.62M | 2.82% | 58,000 -35,000 | -38% | -$5.8M |
|
|
4
Biogen
BIIB
$19.4B
| $9.59M | 2.81% | 29,000 -21,000 | -42% | -$6.95M |
|
|
SLXP
5
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $8.44M | 2.47% | 54,000 +10,507 | +24% | +$1.64M |
|
|
6
Gilead Sciences
GILD
$140B
| $7.66M | 2.24% | 72,000 -108,000 | -60% | -$11.5M |
|
|
CELG
7
DELISTED
Celgene Corp
CELG
| $7.58M | 2.22% | 80,000 -76,781 | -49% | -$7.28M |
|
|
8
Medtronic
MDT
$119B
| $6.87M | 2.01% | +133,800 | New | +$6.87M |
|
9
BioMarin Pharmaceuticals
BMRN
$11.2B
| $6.64M | 1.94% | 92,000 -58,000 | -39% | -$4.19M |
|
|
COV
10
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
| $6.58M | 1.93% | 76,000 -95,000 | -56% | -$8.22M |
|
|
11
AbbVie
ABBV
$372B
| $6.41M | 1.88% | +111,000 | New | +$6.41M |
|
12
Nektar Therapeutics
NKTR
$568M
| $6.13M | 1.8% | 508,000 +248,000 | +95% | +$2.99M |
|
13
Thermo Fisher Scientific
TMO
$186B
| $5.96M | 1.75% | 49,000 +16,000 | +48% | +$1.95M |
|
|
NPSP
14
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $5.82M | 1.71% | 224,000 +157,000 | +234% | +$4.08M |
|
15
CVS Health
CVS
$92.8B
| $5.73M | 1.68% | 72,000 +22,000 | +44% | +$1.75M |
|
16
Acadia Pharmaceuticals
ACAD
$4.38B
| $5.42M | 1.59% | 219,000 -11,000 | -5% | -$272K |
|
|
RAD
17
DELISTED
Rite Aid Corporation
RAD
| $5.41M | 1.58% | 1,118,000 +858,000 | +330% | +$4.15M |
|
18
Incyte
INCY
$16.5B
| $5.25M | 1.54% | 107,000 -26,000 | -20% | -$1.28M |
|
19
Bristol-Myers Squibb
BMY
$96B
| $5.07M | 1.48% | 99,000 +14,000 | +16% | +$717K |
|
|
20
Vertex Pharmaceuticals
VRTX
$100B
| $4.83M | 1.41% | 43,000 -58,600 | -58% | -$6.58M |
|
|
AGN
21
DELISTED
Allergan plc
AGN
| $4.83M | 1.41% | 20,000 -5,000 | -20% | -$1.21M |
|
22
Regeneron Pharmaceuticals
REGN
$61.5B
| $4.6M | 1.35% | 13,000 -9,500 | -42% | -$3.36M |
|
|
PCYC
23
DELISTED
PHARMACYCLICS INC
PCYC
| $4.46M | 1.31% | 38,000 -17,000 | -31% | -$2M |
|
24
Cardinal Health
CAH
$35.5B
| $4.42M | 1.29% | 59,000 -40,000 | -40% | -$3M |
|
|
ICPT
25
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $4.4M | 1.29% | +18,600 | New | +$4.4M |
|